Inferential analysis of the pharmacological properties of the Cervarix® vaccine against papilomavirus

Junchaya Yllescas V.A.; Aliaga Salguero J.J.; Suarez Reynoso L.M. · Vacunas (2022) · DOI: 10.1016/j.vacun.2021.12.003

Resumen

The inferential analysis of the pharmacological properties of the Cervarix® vaccine against papillomavirus reduces the risk of HPV-related cancers and high-grade precursor lesions, specifically cervical. The study methodology is quantitative, through different measurement- based procedures and is non-experimental. Using the Hope-Maximization Cluster, we seek to explain the efficacy of the Cervarix® vaccine in terms of entropy. The results show that the efficacy of Cervarix® vaccines to reduce the risk of CIN2 + and CIN 3 + was over 87.5% for HPV-31 and 81.9% against HPV-45, being in these typologies those with the highest efficacy at the end of the study control. The efficacy of vaccination was estimated at 91.7% and 94.9% associated with HPV-16/18 in CIN2 + and CIN3 + cervical lesions. Meanwhile, the efficacy is between 94.3% and 92.9% for persistent infections at 6 months and 12 months. Entropy decreasingly ranks the efficacy of Cervarix® in HPV-16/18 type lesions as follows: CIN3 + PP, CIN2 + PP, 12-month persistent infection PP, CIN3 + CTV, 6-month persistent infection PP and CIN2 + CTV. Finally, patterns within the observations of vaccine efficacy against non-vaccine oncogenic HPV types; are explained by entropy in decreasing order: VPH- 68/58/52/59/45/31/39/35/33. However, the best cluster accuracy is for HPV-31 and HPV-45 with 100%, followed by 83.33% for HPV-33.

Instituciones: Universidad Privada de Huancayo Franklin Roosevelt